ARDS | Aridis Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-1.65 Insider Own31.53% Shs Outstand30.41M Perf Week-5.28%
Market Cap10.08M Forward P/E1.06 EPS next Y0.26 Insider Trans0.00% Shs Float24.70M Perf Month37.11%
Income-30.40M PEG- EPS next Q-0.41 Inst Own10.20% Short Float / Ratio1.78% / 0.11 Perf Quarter-40.24%
Sales3.10M P/S3.25 EPS this Y57.10% Inst Trans3.28% Short Interest0.44M Perf Half Y-72.27%
Book/sh-0.92 P/B- EPS next Y148.10% ROA-222.30% Target Price10.00 Perf Year-74.82%
Cash/sh0.04 P/C7.76 EPS next 5Y- ROE101.60% 52W Range0.15 - 2.77 Perf YTD-76.74%
Dividend- P/FCF- EPS past 5Y14.20% ROI126.60% 52W High-90.09% Beta0.91
Dividend %- Quick Ratio0.20 Sales past 5Y29.20% Gross Margin- 52W Low83.00% ATR0.05
Employees37 Current Ratio0.20 Sales Q/Q-8.30% Oper. Margin- RSI (14)54.65 Volatility11.11% 15.08%
OptionableYes Debt/Eq- EPS Q/Q48.90% Profit Margin- Rel Volume1.02 Prev Close0.28
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume3.92M Price0.27
Recom2.50 SMA2018.02% SMA5019.18% SMA200-65.00% Volume4,014,578 Change-1.96%
Date Action Analyst Rating Change Price Target Change
Feb-19-20Initiated ROTH Capital Buy $18
Jun-08-23 04:05PM
Jun-01-23 11:24AM
May-31-23 08:00AM
May-25-23 04:05PM
Apr-26-23 12:15PM
07:00PM Loading…
Mar-31-23 07:00PM
Mar-14-23 09:45AM
Mar-13-23 11:15AM
Feb-17-23 08:00AM
Feb-15-23 07:22AM
Feb-06-23 05:34PM
Feb-01-23 09:55AM
Jan-25-23 04:05PM
Jan-17-23 04:30PM
08:30AM Loading…
Dec-28-22 08:30AM
Dec-12-22 08:05AM
Dec-05-22 07:00AM
Nov-30-22 07:00AM
Nov-22-22 09:10AM
Nov-21-22 07:55PM
Oct-12-22 12:16PM
Oct-11-22 05:32PM
Oct-04-22 08:00AM
Sep-27-22 09:20AM
Sep-26-22 03:37PM
Sep-21-22 11:39AM
12:15PM Loading…
Sep-19-22 12:15PM
Aug-16-22 05:25PM
Aug-10-22 10:40AM
Jul-01-22 10:56AM
Jun-30-22 11:49AM
Jun-03-22 08:00AM
May-16-22 05:45PM
Mar-31-22 06:04PM
Feb-17-22 11:41AM
Jan-27-22 06:45AM
Dec-29-21 06:05AM
Dec-21-21 02:55PM
Nov-15-21 10:42AM
Nov-12-21 04:45AM
Nov-10-21 08:00AM
Aug-12-21 09:00AM
Aug-03-21 03:00PM
Aug-02-21 08:00AM
Jul-26-21 08:30AM
Jul-19-21 08:30AM
Jul-13-21 12:22PM
Jul-12-21 04:05PM
Jun-30-21 04:04AM
Jun-09-21 09:21AM
May-11-21 04:01PM
Mar-30-21 05:49PM
Mar-26-21 08:00AM
Mar-08-21 07:30AM
Feb-23-21 07:25AM
Feb-16-21 11:56PM
Nov-24-20 05:30AM
Nov-20-20 04:05PM
Oct-27-20 04:24PM
Oct-19-20 08:30AM
Oct-14-20 05:30AM
Sep-08-20 05:30AM
Sep-04-20 01:32PM
Aug-11-20 04:05PM
Jul-15-20 08:42AM
Jun-26-20 05:30AM
Jun-22-20 05:30AM
Jun-18-20 05:30AM
Jun-15-20 05:30AM
May-12-20 04:05PM
May-07-20 12:08PM
May-04-20 05:30AM
Apr-29-20 05:30AM
Apr-15-20 02:28PM
Apr-08-20 04:59PM
Mar-06-20 04:05PM
Mar-05-20 05:30AM
Mar-04-20 05:30AM
Feb-28-20 02:15PM
Feb-18-20 05:30AM
Jan-28-20 02:56PM
Jan-17-20 05:34AM
Jan-03-20 02:44PM
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.